Pegylated interferon-α2b treatment in melanoma patients: Influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 587-591

  Van Gool, Arthur R ^a   Van Ojik, Heidi H ^a   Kruit, Wim H J ^a   Bannink, Marjolein ^a   Mulder, Paul G H ^a   Eggermont, Alexander M M ^a   Stoter, Gerrit ^a   Fekkes, Durk ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amino acids; Biopterin; Depression; Interferon; Melanoma; Neopterin; Serotonin; Tryptophan

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO ACID DECARBOXYLASE; BIOPTERIN; NEOPTERIN; PEGINTERFERON ALPHA2B; PHENYLALANINE; PTERIDINE; TETRAHYDROBIOPTERIN; TRYPTOPHAN; TYROSINE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINO ACID; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PTERIDINE DERIVATIVE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; MELANOMA; METABOLISM; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ADULT; AGED; AMINO ACIDS; BIOPTERIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPTERIN; PHENYLALANINE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PTERIDINES; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TRYPTOPHAN; TYROSINE;

EID: 3142664534     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000132230.51759.8d     Document Type: Article

References (15)

1. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95:389-396.
2. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876.
3. Van Gool AR, Kruit WHJ, Engels FK, Stoter G, Bannink M, Eggermont AMM. Neuropsychiatric side-effects of interferon-alfa therapy. Pharm World Sci 2003; 25:11-20.
4. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7:468-473.
5. Fernström JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 1972; 178:414-416.
6. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, autoimmune disease and AIDS. Adv Exp Med Biol 1991; 294:425-403.
7. Van Gool AR, Fekkes D, Kruit WHJ, Mulder PGH, Ten Hagen TLM, Bannink M, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003; 119:125-132.
8. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin synthesis, regeneration and functions. Biochem J 2000; 347:1-16.
9. Liberati AM, Horisberger MA, Garofani P, De Angelis V, Ferrajoli A, Di Clemente F, et al. Interferon-alpha-induced biological modifications in patients with chronic myelogenous leukemia. J Interferon Res 1994; 14:349-355.
10. Fekkes D, van Dalen A, Edelman M, Voskuilen AJ. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phtaldialdehyde. J Chromatogr B: Biomed Appl 1995; 669:177-186.
11. Borgdorff P, Fekkes D, Tangelder GJ. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002; 106:2588-2593.
12. Hoekstra R, van den Broek WW, Fekkes D, Bruijn JA, Mulder PGM, Pepplinkhuizen L. Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe medication-resistant depression. Psychiatry Res 2001; 103:115-123.
13. Bonaccorso S, Marino V, Puzella A, Pasquini A, Biondi M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha- based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22:86-90.
14. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54:906-914.
15. Hashimoto R, Ozaki N, Ohta T, Kasahara Y, Kaneda N, Nagatsu T. Plasma tetrahydrobiopterin levels in patients with psychiatric disorders. Neuropsychobiology 1990; 29:140-143.